Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
about
Tamoxifen Resistance: Emerging Molecular TargetsInduction of stable drug resistance in human breast cancer cells using a combinatorial zinc finger transcription factor libraryBazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.A mechanistic study of the effect of doxorubicin/adriamycin on the estrogen response in a breast cancer modelTherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.Global analysis of ZNF217 chromatin occupancy in the breast cancer cell genome reveals an association with ERalpha.The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance.A systems view of epithelial-mesenchymal transition signaling states.RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response.HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models.Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cellsThe turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacyDuring hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein.Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 AbundanceReversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.A novel method of transcriptional response analysis to facilitate drug repositioning for cancer therapy.Headway in resistance to endocrine therapy in breast cancer.A role for estrogen receptor phosphorylation in the resistance to tamoxifen.Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancerUpregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapiesThe molecular profile of luminal B breast cancerBiomarkers characterization of circulating tumour cells in breast cancer patientsBCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinibLong non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcriptionA randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.Identification of breast cancer prognosis markers using integrative sparse boosting.Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.Mechanisms of endocrine resistance in breast cancer.Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.SGK3 is associated with estrogen receptor expression in breast cancer.Tamoxifen resistance in breast cancer.
P2860
Q26739969-01A430B9-3D9B-41A5-86D4-7065F8CF4566Q28479198-8D8EDF77-31EF-46D5-9652-50C82790C428Q30413295-AF0AF4C3-18E9-41F2-BFE7-60BAA5291C72Q30417300-04DE8564-3FAB-4F16-9CA9-BBAAA7A420B0Q30419997-4F580398-76C5-48BC-B301-E3DB9FCE59C3Q33648503-F96F6D52-FC6C-42B8-8C5D-B482A5E247CAQ33788520-EF7B1E7C-5996-4588-8A05-A6A254FBCD48Q33848844-7C371F20-A2E2-4288-8335-701B056194B2Q34311300-95BE42C3-6929-4133-99D3-7445E144C2FFQ34346725-12638CE5-00BC-4751-B107-7076CC8BE520Q34579646-4F9C8442-ED45-46A7-95AD-FA36258F43D6Q34659897-C5C9630F-A5D4-4D6E-B051-7C72F841CD7DQ34793260-BEFC4FDF-8F87-4D1C-940E-75E82404C2C3Q35000243-115BD426-2020-4CAD-8FDA-C4AB6FA4061AQ35000256-623B1E7A-6E17-40C5-9DE0-CFC507461EE2Q35027844-8ADA977D-6E45-4123-8EAB-4832ABDE600CQ35029586-09C4E141-EF3F-432B-B52A-7C6CBBDB06ECQ35040890-C53B0CF7-264C-417A-9151-4E77E51AE801Q35182591-3259C247-41D1-4205-BA22-517733165099Q35558134-0B29341F-5FE2-46DF-8EEE-C51E853C419EQ35652903-2B9F32AB-35CD-4910-A707-A8933B2CAA77Q35667708-D7E819E6-2F2A-406B-B90C-7FD068622DF8Q35684445-C737E93F-78A6-4303-9C72-89A00433364AQ35816378-5318F889-87B3-4C4E-B5FE-AC50F1B42A42Q36067934-077A6FA7-B8BF-4CC6-BB33-1A19E6518B2DQ36127379-D505D4C2-0CCF-4C54-AB3E-BD1E71C54C85Q36196676-3F30F966-B8FE-45B7-B33A-F61E63F2BFB8Q36245346-03DF7E29-0328-4090-8F2E-C8B8E701410CQ36299102-A5E546A2-4B00-4CAF-9679-F959FA1BE111Q36545494-710B1F6A-8852-4CD0-A904-DF17CC703DB0Q36561822-523D7FC4-95C2-42CC-B45B-3EF53860F72EQ36653598-B174BAEB-9190-41C0-8A9D-F27BF0C95E69Q36687678-773CA4E0-DD8B-421E-8CDE-50A7C438651AQ36782224-770FA562-FFEF-4D98-979D-A3E248C47AA2Q36851417-0D00A372-F060-439D-8AD2-3261B2C2B501Q36872440-D7D27FE0-4CA5-43FF-B500-A6DFF1CB3542Q36902056-7617A42A-A641-4B96-9FA3-C6C3AFE2C5EFQ36904280-090A6CB7-B82D-46C9-A09B-4703825F80BAQ36934463-44C6524D-6751-4A2B-BAD5-1BE0AEDE3791Q37224555-9E025ABE-D1AB-428D-A1C2-FE71B9C1F9EC
P2860
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Development of resistance to t ...... ype of breast tumor xenografts
@en
type
label
Development of resistance to t ...... ype of breast tumor xenografts
@en
prefLabel
Development of resistance to t ...... ype of breast tumor xenografts
@en
P2093
P2860
P1433
P1476
Development of resistance to t ...... ype of breast tumor xenografts
@en
P2093
C Kent Osborne
Chad J Creighton
Jiang Shou
Luca Malorni
Rachel Schiff
Shixia Huang
Susan G Hilsenbeck
P2860
P304
P356
10.1158/0008-5472.CAN-08-1404
P407
P577
2008-09-01T00:00:00Z